Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

39,980 stories, page 352 of 667

Advanced search

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Business Brief: Canadian biotech sector finds fresh backing – from foreign investors

The Globe and MailOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum

simplywall.stOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Addressing China’s Rise in Biotech by Removing Barriers: Q&A with John Stanford

Pharmaceutical ExecutiveOriginal source

🌍Aug 4Devicesnews.henryschein.comTier 3 · Secondary coverage

Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance

Henry ScheinOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Danske Bank sees Zealand Pharma as potential "big pharma" takeover target

medwatch.comOriginal source

🇮🇹Aug 4Researchhumanitas.itTier 2 · Direct publisher

Il tuo dentista Humanitas anche ad agosto

Humanitas Research HospitalOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

The Manufacturers Life Insurance Company Sells 155,079 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

SAMSUNG PHARMACEUTICAL.CO.,Ltd. Revenue Breakdown – KRX:001360

TradingViewOriginal source

🇺🇰Aug 4Researchmedsci.ox.ac.ukTier 2 · Direct publisher

The Global Health Network joins the Nuffield Department of Primary Care Health Sciences

Oxford MedicineOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

cbd gummies safety fda warnings 2025 2026 - View ljRKshymF

FC BayernOriginal source

🌍Aug 4discoverynews.google.comTier 2 · Trade media

Biotech Investors Are Waiting For The Wrong Milestone In AI Drug Discovery

insights.citeline.comOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

cbd gummies fda regulation safety third-party testing gmp - View lH6an4juh

FC BayernOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Is CBD Gummies Considered Drugs - View p3La5TMPG

FC BayernOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Digital Health Firm Launches Integrated GLP-1 Program

Streetwise ReportsOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Where AI Fits in the Future of Drug Development

Technology NetworksOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

does making cbd gummier to sell require fda approval - View jKogsldNi

FC BayernOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Has Canada’s biotech moment finally arrived?

The Globe and MailOriginal source

🌍Aug 4discoverynews.google.comTier 2 · Trade media

Amgen contends with data breach, exposing patient information

Pharmaceutical TechnologyOriginal source

🌍Aug 4discoverynews.google.comTier 2 · Trade media

AstraZeneca shares slump after $400bn BMS merger rumours

Pharmaceutical TechnologyOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

WuXi AppTec' s Support for Small and Emerging Biotech Companies: Three Global Examples

EIN NewsOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

FDA peptide vote explained: Why these drugs are not approved yet

FirstpostOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript

GuruFocusOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database

Springer Nature LinkOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Biotech Stocks At 52-Week Highs - ANGO, ANIK, ELOX, YARW, PLSE

RTTNewsOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

TradingViewOriginal source

🇺🇰Aug 4Researchukri.orgTier 2 · Direct publisher

UK strengthens defences against severe solar storms

Medical Research Council (UKRI)Original source

🇩🇪Aug 4Researchuni-heidelberg.deTier 2 · Direct publisher

New Findings on the Eruption History of the West Eifel Maar Volcanoes

Heidelberg UniversityOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical care group: Affordability for prescription drugs requires examination of the entire supply chain

Cardinal NewsOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Biotech CBD Gummies: A Balanced Look at Gummies with Cannabidiol - View LzhhILM6m

FC BayernOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Eli Lilly to offer limited early access to experimental weight-loss drug

medwatch.comOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial

The Clinical Trial VanguardOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

AMSilk collaboration: Biotech silk protein yarns feature in Balenciaga 55th Couture Collection

Yahoo FinanceOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Potential AstraZeneca-Bristol Myers mega-merger could trigger new M&A wave

medwatch.comOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Stephanie Lueras: Why do pharmaceutical commercials have such long warning lists?

Havasu NewsOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Price to sales forward of Shenyang Xingqi Pharmaceutical Co., Ltd. Class A – SZSE:300573

TradingViewOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Former Novo Nordisk North America chief joins board of US biotech company

medwatch.comOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Nurix Starts Phase 3 Trial of Bexobrutideg Against Pirtobrutinib in CLL

The Clinical Trial VanguardOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Price to earnings forward of CH Biotech R&D Co., Ltd. – TWSE:6534

TradingViewOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Which hotels follow FSSAI rules? Maharashtra FDA has no official list

Mid-DayOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Sumitomo Pharma's Enzomenib gets Orphan Drug Designation by US FDA

Indian Pharma PostOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Announcement of Partnership with the Japan Basketball Association (JBA)

chugai-pharm.co.jpOriginal source

🇯🇵Aug 4Industrysumitomo-pharma.comTier 1 · Company source

Sumitomo Pharma Contributes to Relief Efforts for the 2026 Kumamoto Earthquake

Sumitomo PharmaOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

25 Transfers in 20 Years: Who is IAS Tukaram Mundhe, why his FDA crackdown reached Bombay High Court?

India.ComOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical giants AstraZeneca and Bristol-Myers Squibb are in merger talks; combined market value could exceed 2.7 trillion yuan - ChemNet

ChemNetOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says

ReutersOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Beyond the Law: FDA Oversight and Grow Consumer Upgrade-skills Safety

Diario ASOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Barron'sOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Price to book forward of CH Biotech R&D Co., Ltd. – TWSE:6534

TradingViewOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

ORIC Pharmaceuticals (ORIC) Launches Pivotal Phase 3 Trial Amid Mixed Market Signals

GuruFocusOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Nurix enrolls first patient in phase 3 trial for CLL drug

Investing.comOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Nurix Therapeutics Announces First Patient Enrolled in Phase 3 DAYBreak CLL-306 Study of Bexobrutideg in Relapsed/Refractory CLL/SLL

Quiver QuantitativeOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Nurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care

Stock TitanOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

New Castle NewsOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

4MOVING-BIOTECH

The FactsOriginal source

🇯🇵Aug 4Industrysumitomo-pharma.comTier 1 · Company source

Regarding a Report Concerning Sumitomo Pharma

Sumitomo PharmaOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

Business WireOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Have you heard of biotech beauty? We took a closer look

CNNOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Does Tukaram Mundhe Receive Threats After Action Against Restaurants? Maharashtra FDA Chief Responds

NDTV ProfitOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

Peptides Find Their Way to the Public

Native News OnlineOriginal source

🌍Aug 4discoverynews.google.comTier 3 · Aggregated media

FDA Drug Approval Decisions Expected in September 2026 - MPR

Medical Professionals ReferenceOriginal source